Ganga Ranasuriya
Pulmonary Disease · Williamsport, PANPI 1013350362
Payments from drug & device makers
Across 45 payments — averaging $192.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Pulmonx Corporation$409
- Boehringer Ingelheim$160
- GSK$93
- United Therapeutics Corporation$36
- Electromed, Inc.$36
- plus $186 from 9 others
What the payments were for
- Travel & lodging$2,01023%
- Food & beverage$1,13613%
- Education$5,50064%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $7,726 |
| Pulmonx Corporation | 4 | $409 |
| Boehringer Ingelheim | 3 | $160 |
| GSK | 6 | $93 |
| United Therapeutics Corporation | 2 | $36 |
| Electromed, Inc. | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Grifols USA, LLC | 1 | $26 |
| Pharming Healthcare, Inc. | 1 | $24 |
| AbbVie | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,646 in reported general payments places this provider in the 75th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 101 | $1,338,605 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 693 | $504,117 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 343 | $178,576 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 15 | $165,128 |
| Breo ElliptaFluticasone/Vilanterol | 226 | $112,631 |
| Dupixent PenDupilumab | 24 | $91,955 |
| Ambrisentan | 30 | $78,547 |
| Fasenra PenBenralizumab | 12 | $68,560 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 100 | $65,048 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $59,384 |
| Spiriva RespimatTiotropium Bromide | 89 | $56,975 |
| XolairOmalizumab | 16 | $53,349 |
| Dupixent SyringeDupilumab | 14 | $50,316 |
| Tadalafil | 14 | $31,769 |
| Incruse ElliptaUmeclidinium Bromide | 61 | $19,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $160 | $1,470,962313 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $93 | $820,2131,348 claims |
| Grifols USA, LLCProlastin C | $26 | $165,12815 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $35 | $80,968122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Williamsport
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.